Lightspeed Venture Partners led a $250m Series F round in Orca Bio.

Lightspeed Venture Partners, an investment firm, led a $250m Series F round in Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy. With $250m in new equity capital from its two most recent financing rounds, along with a 2025 amendment to its Silicon Valley Bank credit facility providing up to $100m in additional liquidity, Orca Bio possesses the financial strength to scale its commercial operations and advance its clinical pipeline.